Protein Therapy


Also found in: Wikipedia.

Protein Therapy

 

a method of treating diseases in man and animals by injecting protein parenterally, that is, not through the alimentary canal. The proteins are usually administered intramuscularly; they include one’s own blood (autohe-motherapy), the blood of a donor (isohemotherapy), and milk or a solution of casein, milk’s main protein (lactotherapy). Other proteins are also used, including serums and vaccines (serotherapy and vaccinotherapy). Serotherapy and vaccinotherapy are specific in the effect they produce, and the action of a preparation is aimed at the causative agent of a particular infection. All other types of protein therapy are nonspecific in nature and are aimed at increasing the body’s general resistance.

Various chronic and pathological diseases whose course is mild, for example, infectious processes, infectious and allergic processes, and trophic ulcers, are usually indications for protein therapy. Attempts have been made to use nonspecific vaccinotherapy in treating tumors and leukemia by the contemporary French scientist G. Maté.

The products of both autolysis and the decomposition of injected proteins are most important in protein therapy. Their stimulating effect on restoration processes in tissues is well known and is reflected in a series of old biological concepts, including G. Haberlandt’s wound hormones, A. Carrel’s tre-phons, and V. P. Filatov’s biogenic stimulants. Two factors are probably important in the mechanism of protein therapy. The first factor is that the products of protein decomposition activate the body’s own proteins, including those that are immunocompetent, on the basis of the feedback principle. The second factor is that the presence of a large quantity of low-molecular protein precursors in the tissue medium provides the plastic material required for biosynthesis.

The beneficial effect that protein therapy produces in the treatment of tumors is possibly related to the fact that all forms of protein therapy raise the level of normal regenerative processes and that antagonism exists between regeneration and development of the tumor (the Soviet biologist B. P. Tokin, 1940, 1959). This phenomenon was further investigated by Austrian researchers—F. Seilern-Aschpang and his colleagues (1960–63)—who showed that in invertebrates and some vertebrates, for instance, tritons, tumors rarely develop in parts of the body that are easily regenerated, such as the tail and extremities in the triton; when they do develop in such parts of the body, they generally heal by themselves. Involution of a tail tumor in a triton can be accelerated by amputating the healthy part of the organ, thereby triggering regeneration.

G. B. GOKHLERNER

Mentioned in ?
References in periodicals archive ?
Besides genetic engineering and cell engineering techniques, recombinant protein therapy has emerged as a potential therapeutic option.
The trial involved delivery of a protein therapy directly into the brains of Parkinson's patients.
Fibrocell received this funding following a competitive application and evaluation process managed by EBRP's Scientific Advisory Board, or SAB, a panel of physicians and scientists specializing in genetics, hematology, protein therapy and dermatology.
MANF Therapeutics is the intellectual property (IP) holder for MANF-based therapies including protein therapy, gene therapy, and cell therapy.
The company's lead pipeline candidate, TA-46, is a novel protein therapy in development for achondroplasia, the most common form of short-limbed dwarfism.
The company said Alprolix is the first extended half-life and recombinant factor IX Fc fusion protein therapy approved for the treatment of haemophilia B in Saudi Arabia.
Administration of a particular growth factor to stimulate angiogenesis in the affected tissues (or) organ and the protein therapy with single protein agent were not viable options to treat ischemic cardiovascular diseases ([3]).
"Instead of gene editing or protein therapy, we have a new mechanism that may be ripe for proteasomal inhibitors or other targets of the ubiquitination pathway," he added.
Ireland-based biopharmaceutical company Horizon Pharma plc (NASDAQ: HZNP) has agreed to acquire New York, US-based RV001 protein therapy teprotumumab medication provider River Vision Development Corp., the company said.
What they found was a combination of anthrax toxin protein therapy and chemo did just that.